Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 30 October 2017

Indication(s)

Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

Obesity

Obesity

Learn about the complex factors influencing development of obesity.

+ 4 more

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/004281
Orphan designation No
Date First Approved 24-08-2017
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder MendeliKABS Europe Ltd